BAXTER INTERNATIONAL : and bioMerieux Announce CE Mark for NEPHROCLEAR CCL14 Test to Predict Persistent Severe Acute Kidney Injury
MarketScreener,
(NYSE:BAX), a global leader in acute care, and bioMerieux (EPA:BIM), a global leader in in vitro diagnostics, announced the CE…